Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 18,156
- Companies
- 1,062
- Drugs tracked
- 3,385
Quick answer
NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Cariprazine 0.5 mg capsules, hard, Reagila 6 mg hard capsules, Reagila 4.5 mg hard capsules, Reagila 3 mg hard capsules, Reagila 1.5 mg hard capsules
Gedeon Richter Plc.
Adolescent patient (13-17 years of age) with Schizophrenia
1 trial -
Reagila 1.5 mg hard capsules, For the purpose of the clinical study a placebo formulation was prepared using the same white hard gelatine capsule shell., Reagila 3 mg hard capsules, Cariprazine 0.5 mg capsules, hard, Reagila 4.5 mg hard capsules
Gedeon Richter Plc.
Adolescent Patients (13 to 17 years of age) with Schizophrenia
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources